<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464880</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2243</org_study_id>
    <nct_id>NCT00464880</nct_id>
  </id_info>
  <brief_title>Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Cross-Over, 4-Period, 4 Treatment, Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With Incipient/Overt Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the reno-protective effect of renin inhibition with aliskiren as an
      alternative to irbesartan in type 2 diabetes patients with incipient/overt diabetic
      nephropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiproteinuric Effects of Aliskiren (Renin Inhibitor), Irbesartan (Angiotensin Receptor
      Antagonist) and the Combination in Hypertensive Patients With Type 2 Diabetes and
      Incipient/Overt Diabetic Nephropathy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate whether renin-inhibition using aliskiren 300 mg daily could be a treatment alternative to the angiotensin II receptor antagonist irbesartan 300 mg with an equivalent potential for reno-protection</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate whether combination therapy using aliskiren 300 mg daily and irbesartan 300 mg daily has a greater effect on reno-protection than either drug alone</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate whether aliskiren, irbesartan or the combination reduce biomarkers of inflammation and cardiovascular risk</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Diabetes Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and/or female subjects between the ages of 30-80 years with a diagnosis of type 2
             diabetes (World Health Organization criteria)

          -  Body mass index (BMI) within the range of 20 and 32.

          -  Incipient or overt diabetic nephropathy (urinary albumin excretion ≥ 100 but ≤ 2000
             mg/day).

          -  Glomerular filtration rate (GFR) ≥ 40 ml/min documented in the last 4 months prior to
             randomization

          -  To be eligible for randomization, patients must fulfill the following criteria:

               1. Patients on ongoing hypertensive therapy must have a blood pressure ≥ 135/85 mmHg
                  but lower than 170/105 mmHg at Visit 2 (Day -1) AND patients must be on stable
                  antihypertensive medications for at least 8 weeks prior to Visit 2 (run-in
                  period).

               2. Newly diagnosed hypertensive patients must have a blood pressure ≥ 135/85 mmHg
                  but lower than 170/105 mmHg at Visit 2 (Day -1).

          -  Patients must be on stable hypoglycemic medications for at least 8 weeks prior to
             Visit 2 (Day -1).

          -  Patients must be willing and medically able to discontinue all angiotensin-converting
             enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), aldosterone receptor
             antagonist and potassium sparing diuretic medications for the duration of the study.

          -  Female patients must be postmenopausal, have had a bilateral oophorectomy, or have
             been surgically sterilized or hysterectomized at least 6 months prior to screening.

          -  Oral body temperature within the range of 35.0-37.5 °C

          -  Able to provide written informed consent prior to study participation.

          -  Able to communicate well with the investigator and comply with the requirements of the
             study.

        Exclusion Criteria:

          -  Severe hypertension, Grade 3 World Health Organization (WHO) classification (mean
             sitting diastolic blood pressure [MSDBP] ≥ 110 mmHg and/or mean sitting systolic blood
             pressure [MSSBP] ≤ 180 mmHg)

          -  Acetylsalicylic acid (ASA) treatment &gt; 1 g/day or regular use of nonsteroidal
             anti-inflammatory drugs (NSAIDs)

          -  Kidney disease not caused by diabetes or hypertension

          -  Serum potassium &lt; 3.5 or &gt; 5.1 mEq/L

          -  GFR &lt; 40 ml/min/1.73m2 as measured by the Modification of Diet in Renal Disease (MDRD)
             formula

          -  Serum albumin &lt; 2.0 mg/dL

          -  History of hypertensive encephalopathy or cerebrovascular accident in the last 12
             months prior to Visit 1

          -  Transient ischemic cerebral attack during the 6 months prior to Visit 1

          -  Current diagnosis of heart failure (New York Heart Association [NYHA] Class II-IV)

          -  History of myocardial infarction, unstable angina pectoris, coronary bypass surgery,
             or any percutaneous coronary intervention (PCI) during the 6 months prior to Visit 1

          -  Second or third degree heart block without a pacemaker

          -  Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia

          -  Clinically significant valvular heart disease

          -  Type 1 diabetes mellitus

          -  Uncontrolled type II diabetes mellitus; hemoglobin subtype A1C (HbA1C) &gt; 11%

          -  History of malignancy including leukemia and lymphoma (but not basal cell skin
             carcinoma) within the past five years

          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer
             if required by local regulation.

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.

          -  Significant illness within the two weeks prior to dosing.

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of study drugs including, but not limited to,
             any of the following:

               -  History of major gastrointestinal tract surgery such as gastrectomy,
                  gastroenterostomy, or bowel resection

               -  Currently active or previously active inflammatory bowel disease during the 12
                  months prior to Visit 1

               -  Currently active gastritis, duodenal or gastric ulcers, or
                  gastrointestinal/rectal bleeding during the 3 months prior to Visit 1.

               -  Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic
                  function/injury as indicated by abnormal lipase or amylase

               -  Evidence of hepatic disease, a history of hepatic encephalopathy, a history of
                  esophageal varices, or a history of portacaval shunt

               -  Current treatment with cholestyramine or colestipol resins

          -  History of immunocompromise, including a positive test result.

          -  History of a positive hepatitis B surface antigen (HBsAg) or hepatitis C test result.

          -  History of drug or alcohol abuse within the 12 months prior to dosing.

          -  Persons directly involved in the execution of this protocol.

          -  Any condition that, in the opinion of the investigator or the Novartis medical
             monitor, would jeopardize the evaluation of efficacy or safety

          -  History of noncompliance to medical regimens or unwillingness to comply with the study
             protocol

          -  Known or suspected contraindications to the study medications, including history of
             allergy to ACE inhibitors and/or to thiazide diuretics or other sulfonamide derived
             drug

          -  Any surgical or medical condition, which in the opinion of the investigator, may place
             the patient at higher risk from his/her participation in the study, or is likely to
             prevent the patient from complying with the requirements of the study or completing
             the study

          -  Use of any prescription drug or over-the-counter (OTC) medication which is prohibited
             by the protocol.

          -  Patients who previously participated in any aliskiren study.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigative site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2007</study_first_submitted>
  <study_first_submitted_qc>April 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2007</study_first_posted>
  <last_update_submitted>November 28, 2007</last_update_submitted>
  <last_update_submitted_qc>November 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2007</last_update_posted>
  <keyword>Placebo-controlled study</keyword>
  <keyword>assess the renoprotective effect of renin inhibition</keyword>
  <keyword>Aliskiren as an alternative to irbesartan</keyword>
  <keyword>Type 2 diabetes patients</keyword>
  <keyword>incipient/overt diabetic nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

